Oxford Biomedica plc (LON:OXB)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 365.61M |
| Revenue (ttm) | 97.28M |
| Net Income (ttm) | -142.02M |
| Shares Out | 105.97M |
| EPS (ttm) | -1.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 270,579 |
| Average Volume | 174,165 |
| Open | 380.00 |
| Previous Close | 375.00 |
| Day's Range | 342.50 - 380.00 |
| 52-Week Range | 167.00 - 455.00 |
| Beta | 1.01 |
| RSI | 19.28 |
| Earnings Date | Apr 9, 2025 |
About Oxford Biomedica
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and de... [Read more]
Financial Performance
In 2023, Oxford Biomedica's revenue was 89.54 million, a decrease of -36.04% compared to the previous year's 139.99 million. Losses were -157.49 million, 302.2% more than in 2022.
Financial StatementsNews
UK Stock Market News: Anglo American, Mony Group, Oxford Biomedica
Anglo American's demerger on track, record revenues for Mony, Oxford Biomedica FY update eyes EBITDA profitability by H2 ‘25
Small Cap Stocks: Oxford Biomedica, Mirriad, United Oil & Gas
Oxford Biomedica, Mirriad Advertising, Invinity Energy, United Oil & Gas, SysGroup are today's biggest Small Cap stock movers
Half Year 2024 Oxford Biomedica PLC Earnings Call Transcript
Half Year 2024 Oxford Biomedica PLC Earnings Call Transcript
Oxford Biomedica plc (OXBDF) Q2 2024 Earnings Call Transcript
Three Quick Facts: Oxford Biomedica, Rightmove, Galliford Try
Oxford Biomedica, Rightmove, Galliford Try are Tony Cross's three picks from today's financial market news
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today Oxford, UK – 2 September 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, "OXB" or “the Company”), a quality and innov...
Oxford Biomedica announces CFO transition
Oxford Biomedica announces Chief Financial Officer transition - Lucinda Crabtree to join as Chief Financial Officer - Oxford, UK – 17 July 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, "OX...
Oxford Biomedica plc (OXBDF) Q4 2023 Earnings Call Transcript
Oxford Biomedica plc (OTCPK:OXBDF) Q4 2023 Earnings Conference Call April 29, 2024 8:00 AM ET Company Participants Frank Mathias - Chief Executive Officer Sébastien Ribault - Chief Commercial Officer ...
Oxford Biomedica completes acquisition of ABL Europe
Oxford Biomedica completes acquisition of ABL Europe Strengthens Oxford Biomedica's position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple sites...
Oxford Biomedica is hosting a free webinar to share clients' success stories in viral vector manufacturing
Oxford Biomedica is hosting a free webinar to share clients' success stories in viral vector manufacturing Oxford, UK – 23 January 2024: On Wednesday 7 February, Oxford Biomedica, a quality and innova...
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO
Oxford Biomedica plc (OXBDF) Q2 2023 Earnings Call Transcript
Oxford Biomedica plc (OTCPK:OXBDF) Q2 2023 Earnings Conference Call September 20, 2023 8:00 AM ET Company Participants Frank Mathias - CEO Sebastien Ribault - Chief Commercial Officer Stuart Paynter -...
Kyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector® Platform
The non-exclusive, multi-year license and supply agreement enables use of LentiVector ® with any Kyverna product Agreement supports Kyverna's scalability and reliability of CAR T cell manufacturing go...
Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domest...
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domest...
Oxford Biomedica stock soars on rosy forecast, talks to buy ABL Europe
Oxford Biomedica's shares jumped as much as 16% on Wednesday after the British cell and gene therapy company said it would break even earlier than expected and that it was in exclusive talks to buy vi...
Oxford Biomedica to host webinar showcasing the TetraVecta™ system
Oxford Biomedica to host webinar s howcas ing the TetraVect a TM system
Oxford Biomedica Solutions Publishes Peer-Reviewed Journal Article On Novel Dual-Plasmid System, Resulting In Significantly Increased AAV Vector Productivity And Percentage Of Full Capsids Packaged
BEDFORD, Mass., June 08, 2023 (GLOBE NEWSWIRE) -- Oxford Biomedica Solutions LLC, offers The Full Solution™ suite of services, which includes end-to-end development and manufacturing capabilities for ...
Oxford Biomedica launches TetraVecta - the next generation lentiviral vector system
Oxford Biomedica launches TetraVecta TM - the next generation lentiviral vector system
Oxford Biomedica Solutions to Present Company Capabilities and its Platform at American Society of Gene and Cell Therapy in Los Angeles
BEDFORD, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Oxford Biomedica Solutions LLC, offers The Full Solution™ services, which includes end-to-end development and manufacturing capabilities. The scientifi...
Oxford Biomedica plc (OXBDF) Q4 2022 Earnings Call Transcript
Oxford Biomedica plc (OXBDF) Q4 2022 Earnings Call Transcript.
Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023
Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023
Oxford Biomedica Solutions forms new partnerships with three biotechnology companies
Agreements signed with three new partners, bringing the total number of new partners in 2022 to four, ahead of original target Agreements signed with three new partners, bringing the total number of n...
Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domest...